Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alterity Therapeutics Ltd. ( (AU:ATH) ) just unveiled an announcement.
Alterity Therapeutics Ltd. has announced topline data from a Phase 2 study of ATH434, a treatment for Multiple System Atrophy (MSA), presented at the American Academy of Neurology Annual Meeting in 2025. The study was a randomized, double-blind, placebo-controlled trial, indicating a significant step in the company’s research efforts, potentially impacting its position in the neurology field and offering new hope for stakeholders involved in MSA treatment development.
More about Alterity Therapeutics Ltd.
Average Trading Volume: 100
Technical Sentiment Signal: Strong Buy
Current Market Cap: $38.3M
For detailed information about ATH stock, go to TipRanks’ Stock Analysis page.